Analysts Offer Predictions for Envoy Medical Q4 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Stock analysts at Brookline Capital Management lowered their Q4 2024 earnings per share estimates for Envoy Medical in a research note issued to investors on Tuesday, November 19th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.36) per share for the quarter, down from their previous forecast of ($0.29). Brookline Capital Management currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.07) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.30) EPS and FY2025 earnings at ($1.39) EPS.

Separately, Ascendiant Capital Markets upped their price target on shares of Envoy Medical from $8.50 to $8.75 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd.

Envoy Medical Stock Down 0.9 %

Shares of NASDAQ COCH opened at $2.18 on Friday. The company has a 50 day simple moving average of $2.70 and a two-hundred day simple moving average of $2.64. Envoy Medical has a fifty-two week low of $1.01 and a fifty-two week high of $11.46.

Institutional Trading of Envoy Medical

A hedge fund recently bought a new stake in Envoy Medical stock. Virtu Financial LLC acquired a new stake in shares of Envoy Medical, Inc. (NASDAQ:COCH) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,045 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Envoy Medical as of its most recent SEC filing. 8.59% of the stock is currently owned by institutional investors and hedge funds.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.